-
Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB 200 million (USD 29 million). This funding is supported by a consortium of investors including Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings, a leading international sovereign fund, Lilly Asia Ventures, Quan Capital, 3H…
-
Blueray Med Secures Tens of Millions in Series A+ Financing for Advanced Laser Medicine Devices
•
Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The round was led by Hefei Zhonghe Oupu Medical, with the Health Industry Fund Partnership and Shaanxi Investment Fund participating as leading investors. The…
-
Bioyond Robotics Secures $29 Million in Series A and A+ Financing Rounds
•
Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD 29 million) through Series A and A+ financing rounds. The Series A+ funding was co-led by BioTrack Capital and Lilly Asia Fund (LAV), with CICC Qide Fund, a subsidiary of CICC Capital, joining the round.…
-
Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D
•
China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round. The funding round was led by Jiarui Investment and Hesheng Venture Capital. The proceeds from this investment will be directed towards the…
-
Shanghai Best-Link Bioscience Secures $29 Million in Series A Financing for Nano Drug Innovation
•
Shanghai Best-Link Bioscience, LLC, a leading nano drug and drug delivery-focused enterprise based in Shanghai, has reportedly raised close to RMB 200 million (USD 29 million) in a Series A financing round. The funding round was led by Lapam Capital, with significant contributions from Hui Ding Capital and TigerYeah Capital.…
-
Beijing’s Surgerii Secures Series C3 Financing to Advance Endoscopic Surgical Robot Technology
•
Beijing-based endoscopic surgical robot developer, Beijing Surgerii Robotics Company Limited, has reportedly raised hundreds of millions of renminbi in a Series C3 financing round. The round was led by Loyal Valley Capital, with participation from other investors including V Star Capital, SDIC, DNV Capital, and Sunart Investment. Investment to Drive…
-
Willingmed Secures Series B Funding to Advance Clinical Infection Diagnostics
•
Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly secured hundreds of millions of renminbi in a Series B financing round. The round was led by Galaxy Capital, Haier Capital, and Hunan Hi-Tech Venture Capital Health & Elderly Care Fund. The funds raised will…
-
Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’
•
Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics’ A shares and warrants to be traded on the NASDAQ under the ticker symbols “APLM” and “APLMW” respectively. The merger, which…
-
Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade
•
QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi in its inaugural funding round, which was exclusively led by Delian Capital. The capital raised will be directed towards enhancing QL Bio’s “one-stop proteomics platform” and advancing the discovery and clinical application of protein biomarkers.…
-
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of proceeds from previous subscriptions. The company has decided to redirect HKD 509 million (USD 64.8 million), initially intended for the clinical development and commercialization of proxalutamide, pyrilutamide, and AR-PROTAC GT20029, away from clinical studies for…
-
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
•
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV) with Taiwan-headquartered Rxilient Biotech to develop and commercialize its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), across Southeast Asia. The agreement covers key territories including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.…
-
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
-
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D
•
China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private placement of 355 million shares, aiming to collect RMB 1.34 billion (USD 194.8 million). The funds procured will be allocated towards several key projects, including the expansion of peritoneal dialysate production capacity, the construction of…
-
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion Projects
•
China-based Huaren Pharmaceutical Co., Ltd is set to raise RMB 1.34 billion (USD 194.8 million) through a private placement of 355 million shares. The funds raised will be allocated towards several key projects, including the expansion of peritoneal dialysate production capacity, construction of a drug packaging material production base, development…
-
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
•
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of renminbi in a recent financing round, led solely by Cui Capital. The funds will be directed towards the clinical transformation of spatial proteomics tumor immune microenvironment assessment, the development of functional proteomics solutions, and the…
-
WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report
•
China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December 31, 2022. The Contract Development and Manufacturing Organization (CDMO) reported total income of RMB 15.27 billion (USD 2.237 billion), marking a 48.4% increase year-on-year (YOY). Net profits also rose by 47.1% YOY, reaching RMB 5.05…
-
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
•
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used…
-
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
•
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series B financing round, led by Hongfeng Venture. Additional investors included Oriental Wisdom Capital, Zhongchuang Yongjian (Ningbo) Venture Capital, and existing investor Qiao Jing Capital. The funds will be directed towards Phase I clinical studies for…
-
T&L Biotechnology Secures RMB 100 Million in Series A Financing
•
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB 100 million (USD 14.53 million) in a Series A financing round. The round was led by Harvest Capital and Fortune Capital, with participation from Zhiheng (Yantai) Entrepreneurship Service Center. The funds will be used to…
-
Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development
•
Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised RMB 100 million (USD 14.5 million) in an angel financing round. The round was co-led by CAS Investment and Noah Capital. The funds will be used to support technology research and development, new product iteration,…
